News | Antiplatelet and Anticoagulation Therapies

Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease, but it caused almost as many major bleeds and there was no effect on cancers. These are the late-breaking findings presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, and published in the New England Journal of Medicine.

Home September 05, 2018
Home
SCAI and the European Society of Cardiology recently added iFR to their guidelines.
Feature | FFR Technologies | Dave Fornell, Editor

The use of invasive, pressure wire-based fractional flow reserve (FFR) in the cath lab is now considered the gold ...

Home September 05, 2018
Home
News | Remote Monitoring

Biotronik announced it is now the exclusive U.S. distributor for the MoMe Kardia external cardiac diagnostic monitor from digital health company InfoBionic. The device benefits patients suspected of experiencing cardiac arrhythmias.

Home September 05, 2018
Home
News | Pharmaceuticals

The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late-breaking results from the ARRIVE study. Results from ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, with simultaneous publication in The Lancet.1

Home September 04, 2018
Home
News | Blood Testing

Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.

Home September 04, 2018
Home
The Zoll LifeVest wearable defibrillator system was evaluated in the late-breaking VEST Trial presented at ACC 2018 earlier this year. A review article on the results was the No. 1 most viewed article in July and August.
Feature | Dave Fornell, Editor

September 4, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home September 04, 2018
Home
News | Remote Monitoring

Philips announced it has acquired Xhale Assurance Inc., a U.S.-based scale-up company developing and commercializing next-generation sensor technologies. Xhale Assurance’s disposable pulse oximetry sensor is placed on the wing (ala) of the nose, and can reliably measure and transmit a patient’s heart rate and blood oxygenation under low-perfusion conditions that are challenging for conventional fingertip pulse oximetry sensors. Philips said this technology will broaden and differentiate its existing portfolio of oxygen saturation monitoring solutions and allow the company to expand into a currently underserved clinical segment. Financial details of the transaction were not disclosed.

Home August 31, 2018
Home
News | Cardiovascular Business

A new report from data and analytics company GlobalData suggests that Amazon is poised to make huge strides in healthcare as the Internet retail giant prepares to enter a new market. The report highlights a business model that facilitates easier connectivity between providers and patients, a powerful online platform and its artificial intelligence (AI) interface, Alexa.

Home August 31, 2018
Home
News | Cardiac Diagnostics

A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial. Results were presented in a Hot Line Session at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, and published in the New England Journal of Medicine.

Home August 31, 2018
Home
News | Antiplatelet and Anticoagulation Therapies

Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial. The results were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Sept. 25-28 in Munich, Germany, and published in The New England Journal of Medicine.

Home August 31, 2018
Home
Videos | Hemodynamic Support Devices

Behnam Tehrani, M.D., FSCAI, director of the cardiac cath lab, INOVA Heart and Vascular Institute, Fairfax, Va ...

Home August 31, 2018
Home
360 Photos | 360 View Photos

This is a 360 degree photo view inside the neuro-interventional radiology lab at Henry Ford Hospital to show the layout ...

Home August 31, 2018
Home
News | Telecardiology

At the 2018 European Society of Cardiology (ESC) Congress, cardiovascular technology startup Maisense debuted the Freescan telecardiology system that uses a portable device to measure blood pressure and record electrocardiogram (ECG) readings simultaneously.

Home August 30, 2018
Home
360 Photos | 360 View Photos

This is a 360 degree photo inside a Detroit Fire Department ambulance equipped with a new Zoll X Series defibrillator ...

Home August 30, 2018
Home
News | FFR Technologies

Philips announced that the European Society of Cardiology (ESC) has incorporated instantaneous wave-free ratio (iFR) into its updated revascularization guidelines. The new guidelines have provided the highest recommendation (class I A) for iFR alongside fractional flow reserve (FFR) for the objective assessment of the hemodynamic relevance of coronary lesions.

Home August 29, 2018
Home
Subscribe Now